NovoCure Ltd
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
NVCR$12.53-5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of
| December 31, | ||
|---|---|---|
| U.S. dollars in thousands | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $240,821 | $115,326 |
| Short-term investments | 669,795 | 854,099 |
| Restricted cash | 1,743 | 508 |
| Trade receivables, net | 61,221 | 86,261 |
| Receivables and prepaid expenses | 22,677 | 25,959 |
| Inventories | 38,152 | 29,376 |
| Total current assets | 1,034,409 | 1,111,529 |
| Long-term assets: | ||
| Property and equipment, net | 51,479 | 32,678 |
| Field equipment, net | 11,384 | 12,684 |
| Right-of-use assets | 34,835 | 23,596 |
| Other long-term assets | 14,022 | 11,161 |
| Total long-term assets | 111,720 | 80,119 |
| Total assets | $1,146,129 | $1,191,648 |
| December 31, | ||
|---|---|---|
| U.S. dollars in thousands, except share and per share data | 2023 | 2022 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Trade payables | $94,391 | $85,197 |
| Other payables, lease liabilities and accrued expenses | 84,724 | 73,580 |
| Total current liabilities | 179,115 | 158,777 |
| Long-term liabilities: | ||
| Long-term debt, net | 568,822 | 565,509 |
| Deferred revenues | — | 2,878 |
| Long term leases | 27,420 | 18,762 |
| Employee benefit liabilities | 8,258 | 4,404 |
| Other long-term liabilities | 18 | 148 |
| Total long-term liabilities | 604,518 | 591,701 |
| Total liabilities | 783,633 | 750,478 |
| Commitments and contingencies | ||
| Shareholders’ equity: | ||
| Share capital - | ||
| Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 107,075,754 shares and 105,049,411 shares at December 31, 2023 and December 31, 2022 respectively; | — | — |
| Additional paid-in capital | 1,353,468 | 1,222,063 |
| Accumulated other comprehensive income (loss) | (5,469) | (2,433) |
| Retained earnings (accumulated deficit) | (985,503) | (778,460) |
| Total shareholders’ equity | 362,496 | 441,170 |
| Total liabilities and shareholders’ equity | $1,146,129 | $1,191,648 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.